CORT Corcept Therapeutics Inc

Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for...

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 25,953 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average...

Evanson Asset Management LLC lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT Free Report) by 10.7% in the fourth quarter, according to its most recent disclosure with...

A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have lost about 0.6% in that time frame, underperforming the S&P 500.Will the recent negative trend...